<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1819">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460183</url>
  </required_header>
  <id_info>
    <org_study_id>RESP301-002</org_study_id>
    <nct_id>NCT04460183</nct_id>
  </id_info>
  <brief_title>A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19</brief_title>
  <official_title>An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&amp;4 (NOCoV2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thirty Respiratory Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thirty Respiratory Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in&#xD;
      reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison&#xD;
      with SOC alone in hospitalized COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, multicenter, parallel group, concurrent, controlled study&#xD;
      using a sequential adaptive design to evaluate the efficacy and safety of RESP301 plus SOC&#xD;
      versus SOC alone in hospitalized patients with COVID-19 (World Health Organization [WHO]&#xD;
      ordinal scale level 3 or 4).&#xD;
&#xD;
      Approximately 300 participants will be enrolled and randomized 2:1 to the Investigational arm&#xD;
      or the Control arm. The study will be divided into the following periods: Screening period:&#xD;
      (up to 2 days), Intervention (up to 10 days), follow-up (Day 14 and Day 28).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">April 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who progress by at least one level higher on the modified WHO ordinal scale by Day 14</measure>
    <time_frame>From Day 1 to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in room air oxygen saturation (SpO2) from baseline over time</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the modified WHO ordinal scale at each visit up to Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of at least one level lower on the modified WHO ordinal scale</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of at least one level higher on the modified WHO ordinal</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive institutional SOC for the treatment of COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RESP301, a Nitric Oxide generating solution</intervention_name>
    <description>Product application requires inhalation using a standard handheld nebulizer.</description>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Participants will receive institutional SOC for the treatment of COVID-19.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant has laboratory-confirmed SARS-CoV-2 infection as determined by reverse&#xD;
             transcriptase polymerase chain reaction (RT-PCR) or other approved clinical testing&#xD;
             prior to randomization.&#xD;
&#xD;
          2. Participant is hospitalized in relation to COVID-19, requiring supplemental oxygen to&#xD;
             maintain SpO2 at a safe level (WHO level 3 &amp; 4).&#xD;
&#xD;
          3. Participant is capable of giving signed informed consent&#xD;
&#xD;
          4. Participant is male or female. All females of childbearing potential, including&#xD;
             pregnant females, must consent to urine pregnancy testing at screening to be eligible&#xD;
             for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Rapidly deteriorating or likely to require escalation to high flow oxygen, invasive or&#xD;
             non-invasive ventilatory support within 24 hours according to Investigator's opinion.&#xD;
&#xD;
          2. Unable to safely receive a nebulized treatment for approximately 8 minutes according&#xD;
             to Investigator's opinion.&#xD;
&#xD;
          3. Unable to receive or considered ineligible for invasive or non-invasive ventilatory&#xD;
             support.&#xD;
&#xD;
          4. History of methemoglobinemia.&#xD;
&#xD;
          5. Presence of uncontrolled asthma, history of severe bronchospasm.&#xD;
&#xD;
          6. Presence of severe chronic respiratory disease and tracheostomy.&#xD;
&#xD;
          7. Suspected or confirmed untreated, active tuberculosis.&#xD;
&#xD;
          8. Severely immune-compromised participants in Investigator's opinion.&#xD;
&#xD;
          9. Recent active coronary artery disease or decompensated heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alison Bracchi, MSc</last_name>
    <phone>+447763882519</phone>
    <email>alison.bracchi@30.technology</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinesh Saralaya</last_name>
      <phone>44 (0) 1274542200</phone>
      <email>Dinesh.Saralaya@bthft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Onn M Kon</last_name>
      <phone>44 (0)2078861344</phone>
      <email>onn.kon@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pennine Acute Hospitals Trust (Nroth Manchester General Hospital)</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hoyle</last_name>
      <email>Jennifer.Hoyle@pat.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Munavvar</last_name>
      <phone>44 (0) 1772 522416</phone>
      <email>mohammed.munavvar@lthtr.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 3, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

